DR. KERI SWEETEN NOW OFFERING THE BT TEST FOR BREAST CANCER

Dr. Keri Sweeten to offer Provista Life Sciences’ groundbreaking early breast cancer detection test

Phoenix (October XX, 2008) – Dr. Keri Sweeten, Medical Director of Understanding Women,  today announced that she will offer women the BT Test™, the blood test for breast cancer, as part of their annual breast health exam.  The BT Test is a blood test that assists in the early detection of breast cancer.

The BT Test, or Biomarker Translation Test, is prescribed by physicians and is used in conjunction with an annual mammogram to assist in making an earlier and more accurate diagnosis of breast cancer. The BT Test finds multiple cancer-related proteins in the blood and combines the results with the patient’s medical profile to help physicians find breast cancer as early as possible. When detected early, breast cancer has a 96 percent survival rate.

According to the American Cancer Society, women over the age of 40, especially those at higher risk for breast cancer, should be screened for breast cancer annually. The BT Test is available to all women ages 35 to 75, and is strongly recommended by many gynecologists and breast surgeons for women at heightened risk for breast cancer and those under age 50 whose breast density can make it more difficult for a mammogram to detect the presence of cancer.

The BT Test requires a simple blood draw that is sent to Provista Diagnostics, a CLIA (Clinical Laboratory Improvement Amendments) registered Reference Laboratory, and a wholly owned subsidiary of Provista Life Sciences, to be analyzed. The results of the breast cancer test are then sent to the prescribing physician to review with the patient.

Provista Life Sciences will file private insurance claims on behalf of women who take the BT Test. The BT Test is a blood test that assists in the early detection of breast cancer. For women who do not wish to submit an insurance claim, the BT Test is available at a cost of $395.